Тигециклингантимикробное действие, химиотерапевтическая эффективность и побочные реакции

1. http://clinicaltrials.gov/ct2/search

2. Olson M.W., Ruzin A., Feyfant E., Rush T.S. et al. Functional biophysical and structural bases for antibacterial activity of tigecycline. Antimicrob Agent Chemother 2006; 50: 6: 2156-2166.

3. Slover C.M., Rodvold K.A., Danziger L.H. Tigecycline:a novel broad-spectrum antimicrobial. Ann pharmacother 2007; 41: 6: 965-972.

4. Fernandes-Roblas R., Martin-de-Hijas N.Z., Fernandes-Martinez A.T., Garcia-Almeida D. et al. In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. Antimicrob Agent Chemother 2008; 52: 11: 4184-4186.

5. Keeny D., Ruzin A., McAleese F., Murphy E. et al. MarA-mediated overexpression of the AcrAb efflux pump results in decreased susceptibility to tigecycline in Echerichia coli. Antimicrob Chemother 2008; 61: 1: 46-53.

6. Kelesidis T., Karageorgopoulos D.E., Kelesidis I., Falagas M.E. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. Ibid; 62: 5: 895-904.

7. Pankuch G.A., Appelbaum P.C. Postantibiotic effect of tigecycline against 14 Gram-positive organisms. Antimicrob Agent Chemother 2009; 53: 2: 782-784.

8. Castanheira M., Sader H.S., Despande L.M., Fritsche T.R. et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase and metallo-β-lactamase-producing Enterobacteriaceae: report from the SENTRY antimicrobial surveillance program. Ibid; 2008; 52: 2: 570-573.

9. Postier R.G., Green S.L., Klein S.R., Ellis-Grosse E.J. et al. Tigecycline 200 Study Group results of a multicenter randomized open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin structure infections in hospitalized patients. Clin Ther 2004; 26: 704-714.

10. Package insert.Tygacil (tigecycline) for injection. Philadelphia, PA. Wyeth Pharmaceuticals. June 2005.

11. Kaushik V., Beduya D., Kalampokis I., Kohlhoff S. et al. Tetracyclines tigecycline and doxycycline inhibit LPS-induced nitric oxide production by RAW 264.7 murine macrophages. J Immunol 2007, 178: 101. 3.

12. Salvatore C.M., Techasaensiri C., Tagliabue C., Katz K. et al. Tigecycline therapy significantly reduces inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother doi:10.1128/AAC.00979-08.

13. Swoboda S., Ober M., Hainer Ch., Lichtenstern Ch. et al. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. Antimicrob Chemother 2008; 61: 3: 729-733; doi:10.1093/jac/dkm541

14. Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G. et al. Tigecycline

15. cSSSI Study Group; Tigecycline 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skinstructure in fections:results of 2 double-blind phase 3 comparison studies with vancomycin - aztreonam. Clin Infect Dis 2005; 41: Suppl 5: 341-353.

16. Babinchak T., Ellis-Grosse E.J., Dartois N., Rose G. et al. Tigecycline

17. Study Group; Tigecycline 306 Study Group. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections:analysis of pooled clinical trial data. Ibid; 354-367.